Global reach, higher impact
J Cancer 2011; 2:357-359. doi:10.7150/jca.2.357
Short Report
Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Dendreon Corporation, Seattle, WA, USA
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Citation:
Sims RB. Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. J Cancer 2011; 2:357-359. doi:10.7150/jca.2.357. Available from https://www.jcancer.org/v02p0357.htm
Sims RB. Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. J Cancer 2011; 2:357-359. doi:10.7150/jca.2.357. Available from https://www.jcancer.org/v02p0357.htm
Abstract
Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population.
Keywords: sipuleucel-T, metastatic castrate resistant prostate cancer (mCRPC)